The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
作者信息
Simmons H E
出版信息
Int J Health Serv. 1974 Winter;4(1):95-107. doi: 10.2190/TW4Q-WEDA-2Q7V-RHAH.
PMID:4829901
Abstract
摘要
相似文献
1
The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.美国食品药品监督管理局的药品监管体系：对现行安全性和有效性要求的辩护
Int J Health Serv. 1974 Winter;4(1):95-107. doi: 10.2190/TW4Q-WEDA-2Q7V-RHAH.
2
Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
Int J Health Serv. 1974 Winter;4(1):147-55. doi: 10.2190/DCU8-7F68-E48J-4ER5.
3
Present attitudes of governmental drug regulatory agencies.政府药品监管机构目前的态度。
Int J Clin Pharmacol. 1973 Apr;7(2):168-77.
4
Minimum acceptable requirements for introduction and marketing of drugs.
Drugs. 1974;7(6):409-13. doi: 10.2165/00003495-197407060-00001.
5
Drugs on the market.
JAMA. 1970 Feb 16;211(7):1177.
6
Editorial: Bioavailability, bioequivalence and bias.社论：生物利用度、生物等效性与偏倚
Am J Ophthalmol. 1975 Mar;79(3):518. doi: 10.1016/0002-9394(75)90631-5.
7
Nonprescription drugs: an overview.非处方药：概述
Int J Health Serv. 1974 Winter;4(1):125-30. doi: 10.2190/C9CD-1PRB-G60Y-XPVG.
8
The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?《健康法案》中美国食品药品监督管理局对惩罚性损害赔偿的抗辩：是给制药商的礼物还是给公众的礼物？
Fordham Law Rev. 2006 Mar;74(4):2425-60.
9
Medicolegal aspects of drug testing and systems of institutional review.药物检测的法医学方面及机构审查制度
Am J Cardiol. 1974 Oct 1;34(4):482-4. doi: 10.1016/0002-9149(74)90021-6.
10
A perspective on US drug reimportation.对美国药品再进口的一种观点。
JAMA. 2005 Jan 19;293(3):358-62. doi: 10.1001/jama.293.3.358.
Zotero 插件